Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

BACKGROUND: Pixatimod is a unique activator of the Toll-like Receptor 9 pathway. This phase I trial evaluated safety, efficacy and pharmacodynamics of pixatimod and PD-1 inhibitor nivolumab in immunologically cold cancers. METHODS: 3+3 dose escalation with microsatellite stable metastatic colorectal...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemech, Charlotte, Dredge, Keith, Bampton, Darryn, Hammond, Edward, Clouston, Andrew, Waterhouse, Nigel J, Stanley, Amanda C, Leveque-El Mouttie, Lucie, Chojnowski, Grace M, Haydon, Andrew, Pavlakis, Nick, Burge, Matthew, Brown, Michael P, Goldstein, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843174/
https://www.ncbi.nlm.nih.gov/pubmed/36634920
http://dx.doi.org/10.1136/jitc-2022-006136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843174/
https://www.ncbi.nlm.nih.gov/pubmed/36634920
http://dx.doi.org/10.1136/jitc-2022-006136

Ejemplares similares